U.S. Markets closed

Neurocrine Biosciences Soars on Third-Quarter Results -- Biotech Movers

Armie Margaret Lee

The San Diego firm said net product sales of Ingrezza, a treatment for tardive dyskinesia, were $45.8 million during the quarter. The FDA approved Ingrezza in April.